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2ABSTRACT
Monobodies are small engineered binding proteins that, upon expression in cells, can 
inhibit signaling of cytosolic oncoproteins with outstanding selectivity. Efficacy may be 
further increased by inducing degradation of monobody targets through fusion to the 
VHL substrate receptor of the Cullin2-E3 ubiquitin ligase complex. However, potential 
therapeutic use is currently limited due to the inability of monobody proteins to cross 
cellular membranes. Here, we use a chimeric bacterial toxin, composed of the Shiga-like 
toxin B (Stx2B) subunit and the translocation domain of Pseudomonas aeruginosa 
exotoxin A (ETA-II) for delivery of VHL-monobody protein fusions to target 
endogenous tyrosine kinases in cancer cells. Depending on the expression of the Stx2B 
receptor Gb3 on the cell surface, we show that monobodies are taken up by an endocytic 
route, but are not degraded in lysosomes. Delivery of monobodies fused to a nuclear 
localization signal resulted in accumulation in the nucleus, thereby indirectly, but 
unequivocally demonstrating cytosolic delivery. Delivery of VHL fused to monobodies 
targeting the Lck tyrosine kinase in T-cells resulted in reduced Lck protein levels, which 
was dependent on expression of Gb3. This led to the inhibition of proximal signaling 
events downstream of the T-cell receptor complex. This work provides a prime example 
of the delivery of a stoichiometric protein inhibitor of an endogenous target protein to 
cells and inducing its degradation without the need of genetic manipulation of target cells. 
It lays the foundation for further in vivo exploitation of this delivery system.
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3INTRODUCTION
Targeted cancer therapeutics have improved the survival in several cancer types. Over 
the past two decades, ~20 therapeutic antibodies and ~35 small-molecule enzyme 
inhibitors targeting key driver oncogenes were developed. 1,2 Antibodies bind their 
targets with exquisite selectivity and high affinities, but their application is limited to 
extracellular targets, as they cannot cross cellular membranes. In contrast, many small 
molecule inhibitors readily enter cells to inhibit intracellular targets. Engineered binding 
proteins derived from non-antibody scaffolds (monobodies, DARPins, repebodies, 
affibodies and others) and mini-immunoglobulin scaffolds (scFvs, Fabs, nanobodies and 
others) can be readily developed to bind with high affinity and higher selectivity than 
most small chemical inhibitors to any intracellular target of choice. 3,4 Their smaller sizes, 
typically only 10-20 kDa, as compared to a full IgG antibody (~150 kDa) promise better 
tissue penetration. Still, efficient and tumor-cell selective intracellular protein delivery 
methods are lacking. 
Among the well-studied non-antibody scaffolds are monobodies, synthetic in vitro-
evolved binders built on the fibronectin type III (FN3) domain. 5,6 Monobodies are only 
~10kDa in size, lack cysteine residues and can bind their target proteins with low 
nanomolar affinity. The lack of possible disulfide bridges enables their expression and 
activity in the reducing environment of the cytoplasm. We and others have extensively 
used monobodies to target various intracellular oncoproteins, including tyrosine kinases, 
tyrosine phosphatases, small GTPases and epigenetic regulators. 7-12 Upon cytosolic 
expression by plasmid transfection or retro-/lenti-viral gene transfer, monobodies 
selectively inhibited target-dependent signaling events. In this study, we employ 
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4monobodies Mb(Lck_1/3) and AS25 that inhibit signaling of the Lck and Bcr-Abl 
tyrosine kinases, respectively, by targeting its SH2 domains. 9,10 
Targeted protein degradation can lead to a more sustained reduction of signaling, as 
compared to a small molecule inhibitor alone, as the degradation of the protein-of-
interest also eliminates its scaffolding functions. 13,14,15 Proteolysis-targeting chimeras 
(PROTACs) are chemical probes of a protein-of-interest conjugated to a ligand that 
hijacks either the cereblon or the Cullin2 E3 ligase complex. In contrast to the PROTAC 
approaches, which require selective high affinity molecular probes that are not available 
for a large number of therapeutic targets 15, monobodies can be readily developed against 
virtually any target of choice. Recently, a monobody (or nanobody) was fused to the 
Von-Hippel-Lindau (VHL) protein, the substrate receptor of the Cullin2/RBX1 E3 
ubiquitin ligase complex, which resulted in degradation of its target protein upon 
expression in cells. 16 Other approaches include the Trim-Away method17, which requires 
the genetic overexpression of the E3 ubiquitin ligase Trim21 and electroporation of the 
cells with antibodies against the target protein. However, the therapeutic use of these 
approaches is limited, as methods to efficiently deliver recombinant binders to cells are 
lacking.
Several methods for intracellular delivery of various macromolecular cargos have been 
studied over the past decades, starting with cell penetrating peptides (CPPs) and 
including liposomal carriers, diverse nanoparticles and bacterial or viral proteins. 18 In 
particular, the efficiency of CPP-mediated delivery is highly cargo- and cell type-
dependent. 19 Although several clinical trials with CPPs to deliver drugs, therapeutic 
peptides and siRNAs to cells have been conducted, none of them has resulted in approval 
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5of a product. 20 Most protein delivery studies use cytotoxic proteins, fluorescent 
probes/proteins or enzymes, such as Cas9, CAT or luciferase, as model cargo. However, 
an extremely low concentration of such cargos reaching the cytosol can lead to a 
measurable readout of cellular delivery, even if delivery is very inefficient or the 
majority of the cargo is entrapped in the endocytic pathway. Examples where protein 
delivery of a synthetic binding protein of an endogenous oncoprotein results in inhibition 
of a particular cancer pathway are very limited. 21
Bacterial toxins have naturally evolved to enter the host cells' cytosol and to escape 
endosomal degradation. Both high cellular uptake and significant cytoplasmic 
accumulation of heterologous cargo proteins was achieved with different toxins. 22 
Moreover, cell-selectivity is achieved by binding to a specific host cell receptor. 
Particularly useful are the so-called AB toxins, which are composed of two subunits, A 
(for activity, encoding cytotoxic effectors) and B (for binding and uptake into the 
cytosol). 23,24 We have adapted a chimeric construct which combines the B-subunit of 
Shiga-like toxin (Stx2B), secreted by certain pathogenic Escherichia coli strains, with 
domain II (B subunit) of Exotoxin A, secreted by Pseudomonas aeruginosa (ETA-II). 
Stx2B is pentameric and binds to globotriaosylceramide (Gb3), a glycosphingolipid, 
which is present on many human cell types and is upregulated in a number of tumors. 25-
28 Both Stx2B and ETA-II follow a retrograde trafficking route in the host cell after 
endocytosis to escape endosomes. Following furin protease cleavage within the ETA-II 
domain, the C-terminal portion reaches the cytosol via the Golgi apparatus and the 
endoplasmatic reticulum (ER). (Figure 1a) The Stx2B-ETAII chimera has been 
developed and successfully used to deliver EGFP, certain enzymes and an ERK2 kinase 
Page 5 of 30
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
6regulator, and has proven to be more stable when fused to cargo proteins than Stx2B 
alone. 29,30
Here, we describe and validate the receptor-specific cytoplasmic delivery of monobody-
VHL fusion proteins to cancer cells using a chimeric toxin delivery system, resulting in 
targeted degradation and signaling inhibition.
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7RESULTS AND DISCUSSION
Cellular uptake of Stx2B-ETA-II-cargo fusion proteins
The lack of efficient protein delivery to the cytoplasm and nucleus of cancer cells is the 
major bottleneck for the therapeutic use of synthetic binding proteins. Here, we assess 
the ability of a chimeric Stx2B-ETA-II toxin system to deliver engineered monobody 
binders into the cytosol of cancer cells. As the efficiency of any protein delivery system 
is highly cargo dependent 19, it is unclear if sufficient amounts of functional monobody 
can be delivered to target an endogenous signaling pathway. We generated constructs for 
recombinant expression of either GFP (as control) or different monobodies fused to the 
C-terminus of Stx2B-ETA-II. (abbreviated as 'toxin' in the remaining paper; Figure 1a) In 
addition, the constructs contain the ER-retention motif KDEL at the C-terminus, 
enhancing retrograde transport after furin cleavage of the ETA-II domain. We have also 
generated constructs incorporating a SNAP-tag for efficient and site-specific labeling 
with fluorescent benzylguanine (BG) substrates before or after delivery. 31 Alternatively, 
and to compare delivery efficiency with the bigger SNAP-tagged constructs, variants 
with a cysteine at the C-terminus of the monobody were generated, allowing for labeling 
with a maleimide-coupled fluorophores before delivery. The purity and pentameric 
nature of all recombinant toxin fusion proteins following affinity purification using a C-
terminal 6xHis tag was confirmed by size exclusion chromatography. (Figure 1b, 1c, 1d 
and Supplementary Figure 1)
We first tested the uptake efficiency of the purified toxin-monobody fusion proteins in 
HeLa cells. The expression of the Stx2B receptor Gb3 on the surface of HeLa cells was 
confirmed by flow cytometry and the broad distribution of expression levels is in line 
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8with literature reports. 32 (Supplementary Figure 2a) Incubation of HeLa cells with a 
toxin-emGFP fusion protein resulted in a fluorescent signal in the cytoplasm already after 
15 minutes of incubation, demonstrating the correct folding of the recombinant toxin 
proteins and their ability to deliver a fluorescent protein. (Figure 2a) Similarly, when 
using a fluorescently labeled monobody as a cargo, we observed an increase in the mean 
fluorescence over time and efficient uptake at low micromolar concentration. (Figure 2b 
and 2c) 
Uptake and absence of degradation of toxin-SNAP-monobody proteins
To distinguish internalized from surface-bound cargo protein, we made use of cell-
permeable and -impermeable fluorogenic SNAP-substrates. We first labeled toxin-
SNAP-monobody protein with the cell-impermeable SNAP substrate BG-Alexa-Fluor-
647 (BG-647). Upon incubation with HeLa cells, a weak fluorescent signal was observed 
in the cytoplasm after only 30 minutes of incubation, which increased with incubation 
time. (Figure 3a) The staining pattern and increase in signal intensity over time are in line 
with the data shown in figure 2a, 2b and 2c, suggesting a similar uptake mechanism and 
efficiency independent of cargo and fluorescent label. Incubation of the cells with 
unlabeled toxin-SNAP-monobody constructs and subsequent addition of the cell-
permeable BG-Silicorhodamine (BG-SiR) after delivery only showed staining inside the 
cells. In contrast, no staining was observed with the impermeable BG-647 probe, 
demonstrating the effective internalization of the toxin-monobody proteins and absence 
of cell-surface-bound protein. (Figure 3b)
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9To assess the fate of the monobody proteins within the cell over longer time periods after 
delivery, we incubated HeLa cells with BG-647-labeled toxin-SNAP-monobody fusion 
proteins for 1 hour, followed by a washing step and further incubation in growth medium 
for up to 24 hours. (Figure 3c) The presence of a robust cytoplasmic fluorescent signal 
even after a 24-hour incubation in growth medium showed that the proteins remain 
present in the cell with no signs of degradation.
Endocytosis and cytosolic delivery of toxin-monobody fusions
In order to study the uptake route, HeLa cells were incubated with toxin-monobody 
fusion proteins and co-localization with a marker for early endosomes, EEA1, was 
monitored. We observed co-localization of the delivered protein with EEA1-positive 
vesicles, which increased over time and decreased thereafter. (Figure 4a and 
Supplementary Figure 3) We next tested, if the delivered proteins are trafficked to 
lysosomes, by analyzing their co-localization with the lysosomal marker Lamp1. Minor 
co-localization between Lamp1 and protein signals was observed at the earliest timepoint 
of incubation, and further decreased upon prolonged incubation in growth medium. 
(Figure 4b and Supplementary Figure 4) These results show uptake of the delivered 
proteins via endocytosis and indicate their translocation to a compartment other than the 
lysosome.Since unequivocal cytosolic localization is difficult to determine by 
microscopy due to the complexity of endocytic compartments and dynamic membrane 
interchange, we used an indirect approach by adding a Nuclear Localization Signal (NLS) 
to the toxin-monobody construct. (Figure 1a) As NLS recognition takes place in the 
cytosol, increased nuclear accumulation is therefore an indirect measure of the amount of 
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10
protein that has reached the cytosol and can be monitored by co-localization with a DNA 
marker. Furthermore, this technique allows imaging of live cells. We observed an NLS-
dependent increase in nuclear localization of toxin-monobody fusion proteins 24 hours 
after their delivery, demonstrating at least partial cytosolic uptake of toxin-monobody 
fusion proteins after delivery. (Figure 4c and Supplementary Figure 5)
Gb3-dependent monobody delivery in cancer cells
To test if the uptake of Lck-targeting monobodies is Gb3-dependent, we used Gb3-
negative Jurkat T-cells, which we transduced to inducibly express the lactosylceramide-
4-alpha-galactosyltransferase (A4GALT; Gb3 synthase). (Supplementary Figure 2b) 
A4GALT catalyzes the transfer of galactose to lactosylceramide to form Gb3. We 
monitored the uptake of BG-647 labeled toxin-SNAP-ML3 monobody in Jurkat cells by 
flow cytometry. Induction of A4GALT expression and incubation with toxin-SNAP-
ML3 showed increased fluorescence, demonstrating that protein uptake is Gb3 receptor 
dependent. (Figure 5a) To confirm that this signal comes from internalized protein and 
not from surface-bound protein, we first incubated cells with unlabeled protein and 
subsequently added the cell-impermeable BG-647 SNAP substrate. These cells emitted a 
greatly reduced fluorescent signal as compared to cells incubated with pre-labeled 
protein, demonstrating that the fluorescent signal stems from intracellularly delivered 
proteins and that very little protein remains bound to Gb3 on the cell surface or 
unspecifically to the membrane. (Figure 5a)
While the Stx2B receptor Gb3 is not expressed on many leukemia cell lines, its inducible 
expression gave us the opportunity to control receptor-dependent uptake of toxin-
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monobody fusion proteins. In contrast, Gb3 is expressed in many primary human tissues 
and Gb3 expression is upregulated in certain tumor cells, such as Burkitt’s lymphoma 
cells, gastric adenocarcinoma, colorectal cancer cells and others 25-28 and may therefore 
enable tumor cell-selective delivery of monobodies in vivo. Additionally, and in order to 
broaden the applicability of this approach to Gb3-negative tumors, Stx2B could be 
replaced by binders to other receptors, e.g. repebodies binding to EGFR30 or a DARPin 
targeting EpCAM23, thereby exploiting engagement of tumor cell-specific receptors.
Expression of VHL-monobodies result in Lck degradation
We have previously shown that the expression of monobodies ML1 and ML3 targeting 
the Lck kinase inhibited T cell receptor (TCR) signaling.10 We reasoned that we could 
increase the inhibitory efficacy of ML1 and ML3 by degrading Lck using VHL-
monobody fusion proteins. Upon inducible expression of VHL-ML1 or VHL-ML3, but 
not VHL-HA4_YA, a non-binding control monobody7 in Jurkat T-cells, Lck protein 
levels were reduced by ~50%. (Supplementary Figure 6a and 6b) Furthermore, the 
phosphorylation of Zap-70, a direct Lck substrate, was substantially reduced in cells 
expressing VHL-ML1 or VHL-ML3, but not VHL-HA4_YA, both in unstimulated cells 
and in cells stimulated with an anti-TCR antibody. (Supplementary Figure 6c and 6d) 
These results demonstrate the utility of VHL-fused monobodies to degrade Lck and 
enhance inhibition of TCR signaling.
Delivery of VHL-monobodies result in Lck degradation and inhibition
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12
The targeted degradation of endogenous proteins without the need of genetic 
manipulation of cells is of great utility for both research purposes and novel therapeutic 
avenues. We therefore assessed whether the bacterial toxin delivery system could be used 
to deliver VHL-monobody fusion proteins and to degrade target proteins.
Toxin-VHL-ML3 and toxin-VHL-HA4_YA fusion proteins were recombinantly 
expressed and purified. (Supplementary Figure 7) Upon incubation of toxin-VHL-ML3, 
but not toxin-VHL-HA4_YA or toxin-emGFP with Jurkat T cells, we observed a ~50% 
decrease of the Lck protein level, indicating protein delivery at similar efficiency as with 
lentiviral expression. (Figure 5b and 5c) Toxin-VHL-ML3 had no effect on Lck levels in 
cells that did not express Gb3, demonstrating the exquisite receptor-specificity of this 
approach. (Figure 5b and 5c) Immunoblot analysis readily detected the delivered His-
tagged proteins. (Figure 5b) Here, an additional smaller band to the full-length proteins 
was observed in cells incubated with toxin-ML3 and toxin-emGFP, which corresponds to 
the size of the protein C-terminal to the furin cleavage site. (C-terminal part of ETA-II, 
monobody/emGFP, 6xHis-tag and KDEL sequence, Figure 1a and 5b, bottom panel) 
This indicates that the protein is cleaved by furin along the retrograde pathway. No signal 
for delivered proteins were detected in cells incubated with ML3 alone and in cells not 
expressing Gb3, further demonstrating specific and receptor dependent uptake. (Figure 
5b, bottom panel)
Interestingly, the delivered VHL-fusion constructs were detected at lower levels in cells 
upon delivery (Figure 5b, bottom panel) than the control proteins not bearing the VHL 
sequence. This could indicate that the uptake is less efficient due to the larger construct 
size or due to a higher rate of autodegradation.
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13
To the best of our knowledge, we demonstrate for the first time the cytosolic delivery of 
a functional protein binder inducing the targeted degradation of an endogenous target. 
We also assessed the effects on cell viability after prolonged incubation with chimeric 
toxin proteins. Although cell viability remained close to 100% upon delivery of toxin-
VHL-monobody, it was reduced when incubating cells for more than 24 hours with 
toxin-monobody proteins lacking VHL. (Supplementary Figure 8) This was observed in 
different cell lines, with different monobodies, including a non-binding control and was 
dependent on the Gb3 receptor. (Supplementary Figure 8) Given the uptake mechanism 
that exploits retrograde transport through the secretory pathways, it is a plausible 
hypothesis that the accumulation of proteins in the ER may lead to ER-stress through the 
UPR pathway. 33-35 The presence of a relatively unstable domain such as VHL might 
facilitate unfolding by chaperones and translocation to the cytosol, explaining the 
absence of toxicity upon toxin-VHL-monobody delivery as compared to the mild toxicity 
of the toxin-monobody proteins lacking VHL.
We finally wanted to assess whether the reduced Lck protein levels upon VHL-ML3 
protein delivery also result in inhibition of TCR signaling, as upon genetic expression of 
VHL-monobodies. We stimulated Jurkat cells with the anti-TCR antibody after 
incubation with toxin-VHL-monobody proteins and observed reduced phosphorylation of 
Zap70 upon delivery of VHL-ML3 as compared to VHL-HA4_YA. (Figure 5d and 5e) 
These results indicate that VHL-monobody fusion proteins can be delivered, resulting in 
reduction of endogenous target protein levels and inhibition of downstream signaling.
Future outlook
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14
While the serum stability and plasma half-life of toxin-monobody proteins remain to be 
tested, the relatively large size of these pentameric proteins is expected to increase 
plasma half-life, compared to the known rapid clearance of small protein binders. 36 
However, a likely limitation for the in vivo use of the described method might be 
systemic immunogenicity derived from the toxin proteins. Previously described methods 
to remove immunogenic epitopes through protein engineering or to encapsulate proteins 
could be used to shield the delivered recombinant construct. 37 Alternatively, the amount 
of delivered proteins could be reduced through localized applications, such as 
intratumoral injections or topical application.
The modularity of the described toxin delivery system is of great advantage for various 
chemical biology and therapeutic applications. As shown, VHL, the self-labeling SNAP-
tag and a nuclear localization signal can be added to the construct while retaining 
delivery efficiency. Monobodies can be engineered to bind any intracellular protein of 
choice Even the addition of a tandem monobody – either binding to two different 
epitopes on the same domain or engaging two different domains of the same protein – 
could be highly beneficial and boost potency of targeting, as previously demonstrated. 
8,38 Combining the delivery of an allosteric monobody, like ML3, which binds to the SH2 
domain of Lck, with an ATP-competitive small molecule kinase inhibitor, targeting the 
ATP binding site of Lck or a downstream kinase, is an emerging and highly attractive 
concept. A major advantage of such a combination could include reduced resistance 
development.
In conclusion, we used a chimeric bacterial toxin to achieve cytoplasmic delivery of a 
functional monobody protein bound to the substrate binding receptor of an E3 ubiquitin 
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15
ligase complex, resulting in targeted degradation and inhibition of a key signaling 
protein. This versatile approach offers great promise for future therapeutic use and to 
specifically degrade any protein of interest without the need of genetic manipulation of 
cells.
METHODS
Plasmids and reagents
The cDNA encoding A4GALT was obtained from the Gene Expression Core Facility at 
EPFL and cloned into the pEM24 vector (modified pCW22 39 obtained from E. Meylan, 
EPFL) using InFusion recombinase (Clontech), for lentiviral transduction and inducible 
expression. The cDNA encoding VHL was obtained from the laboratory of G. Sapkota 
(Dundee University, UK) and VHL-monobody constructs were cloned into the pEM24 
vector using InFusion cloning. All constructs in the pEM24 vector were transformed in 
the E. coli strain HB101. The lentiviral expression system vectors pCMV-R8_74 
(encoding gag and pol proteins) and pMD2_G (encoding VSV-G envelope) were kind 
gifts from I. Barde (Trono Lab, EPFL).
A C-terminal cysteine was introduced at the C-terminus of the monobodies by site 
directed mutagenesis using the Quik-change site directed mutagenesis kit (Stratagene). 
The pET21a vector for recombinant expression containing the Stx2B-ETAII construct 
was obtained from the laboratory of H.-S. Kim (KAIST, Korea), and monobody, SNAP-
monobody, VHL-monobody or monobody-NLS constructs were cloned into this vector. 
All DNA constructs were verified by DNA sequencing, performed by Microsynth.
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Antibodies and reagents
Antibodies against (Lck (#2657), Zap70 (#2709), pZap70(Y319) (#2701) and 
pZap70(Y493) (#2704) were purchased from Cell Signaling Technology, the antibody 
used for Jurkat cell stimulation (T-cell receptor, clone C305 [#05-919)) was purchased 
from Millipore, antibodies against beta-Actin (MA1-140) and against the Myc tag (MA1-
21316-D800, directly coupled to DyLight800) were purchased from ThermoFisher. The 
antibody against penta-His (34610) was purchased from QIAGEN. Anti-mouse 
IRDye680 (926-32210), Anti-mouse IRDye800 (925-32210) and anti-rabbit IRDye680 
(925-68071) antibodies were purchased from LiCOR. Antibodies used for 
immunofluorescence against EEA1 (BD610547), Lamp1 (BD555798) and anti-Mouse 
coupled to Fluorescein isothiocyanate (FITC, F0257) were purchased from Sigma. 
Maleimide coupled to AlexaFluor488 was purchased from ThermoFisher (A10254), 
fluorogenic SNAP substrates (Benzylguanine-Silicorhodamine and Benzylguanine-
AlexaFluor647) were a kind gift from K. Johnsson (EPFL). FITC-conjugated anti-CD77 
antibody (357103) was purchased from Biolegend.
Protein labeling
Toxin-Monobody constructs bearing a C-terminal cysteine were incubated with 
maleimide coupled to AlexaFluor488 (ThermoFisher) at a 10-fold molar excess over 
night at 4°C with mild shaking in the dark. Proteins bearing a SNAP-tag were incubated 
with Benzylguanine-AlexaFluor647 at 5-fold molar excess for 2 hours in the dark at 
room temperature with mild shaking. 
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Labeled protein was purified using a PD SpinTrap G-25 or PD MidiTrap G-25 by 
following the manufacturer's instructions and using SEC buffer (25 mM Tris-HCl pH 7.5, 
150 mM NaCl, 5% (w/v) glycerol).
For in-cell labeling, cells previously incubated with the SNAP-protein were incubated 
with 500 nM permeable SNAP substrate (benzylguanine-Silicorhodamine) for 30 
minutes, prior to washing with PBS.
Image processing and analysis
After image acquisition, the images were processed and analyzed in Fiji/ImageJ software 
using the Common Tools Plugin (BIOP, EPFL). The same settings were applied to all the 
images from one experiment. 
For colocalization analysis, regions of interest (ROIs) describing the cell area were 
selected from the processed images using the MultiManualSelect tool (BIOP, EPFL). All 
experiments were done in at least two biological repeats and at least 15-20 images per 
experimental condition were analyzed with 1-4 cells per image. After selecting ROIs, a 
threshold algorithm was selected for each channel to distinguish true signal from 
background noise for each image. Mander’s overlap coefficients between the channels 
for the protein signal and the antibody signal were calculated using the JaCOP tool 
(BIOP, EPFL), for each individual ROI by averaging over the different z-stacks. 
For nuclear localization analysis, an ImageJ script was used to define de Hoechst-stained 
nucleus as ROI in each cell, measure the signal from the 488nm channel in the defined 
ROI (nucleus) for each z-plane individually and average the values over the different z-
planes.
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A detailed description of Methods is available as Supporting Information. 
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Supplementary Methods
Supplementary Figures 1-9
FIGURE LEGENDS
Figure 1. Expression and purification of recombinant toxin-monobody fusion proteins. (a) 
Schematic of the constructs with their monomeric and pentameric size in kDa. (b) Size 
exclusion chromatogram of StxB-ETAII-ML3 as representative for the other purified 
proteins. (c) Coomassie stained SDS-PAGE gel of StxB-TDP-ML3 with the fractions 
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from the Ni-NTA purification (L=crude lysate, FT=flow-through, W=wash, E=elution) 
and the main peak of the SEC after concentration. (d) Corresponding immunoblot with 
an antibody recognizing penta-His.
Figure 2. Toxin-monobody delivery in HeLa cells. (a) HeLa cells were incubated with 1 
µM toxin-emGFP and imaged at different time points. (b) HeLa cells were incubated 
with 1 µM AF488-labeled toxin-AS25 9 and imaged at different time points. (c) HeLa 
cells were incubated with 0.1 µM or 1 µM or 2.5 µM toxin-AS25 for 1h. Live cells were 
imaged on a confocal microscope. Scale bars correspond to 10 µm. Image quantification 
of these experiments are shown in Supplementary Fig. 2
Figure 3. Life-cell imaging of delivery of SNAP-tagged toxin-monobody fusion proteins 
in HeLa cells. (a) HeLa cells were incubated with toxin-SNAP-AS25 prelabeled with 
BG-647 for the indicated durations. (b) HeLa cells were incubated with unlabeled toxin-
SNAP-ML3 for the indicated durations, washed and incubated with either BG-SiR or 
BG-647 for 30 min. The bottom image shows HeLa cells incubated only with BG-SiR, 
but no protein. (c) HeLa cells were incubated for 1h with BG-647-labeled toxin-SNAP-
AS25, washed and incubated in medium for 2.5, 9 or 24 hours. Live cells were imaged 
on a confocal microscope. Scale bars correspond to 10 µm. Image quantification of these 
experiments are shown in Supplementary Fig. 2
Figure 4. Subcellular localization of toxin-monobody fusion proteins. (a) Colocalization 
analysis of BG-647 labeled toxin-SNAP-AS25 with early endosomes in HeLa cells. 
HeLa cells were incubated with the protein for 10 minutes, washed, incubated in growth 
medium and fixed after 0, 10 or 30 min or 1h. Early endosomes were stained with an 
antibody against EEA1 and the Mander’s overlap coefficient 2 between the antibody and 
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the protein signals is plotted for each cell. (Plots of Mander’s 1 versus 2 are shown in 
supplementary figure S3.) P-values were calculated using a Welch two-sample t-test. (b) 
Colocalization analysis of BG-647 labeled toxin-SNAP-AS25 with lysosomes in HeLa 
cells. Lysosomes were stained with an antibody against Lamp1 and the Mander’s overlap 
coefficient 2 between the antibody and the protein signals is plotted for each cell. (Plots 
of Mander’s 1 versus 2 are shown in supplementary figure S4.) (c) Uptake of NLS-
tagged toxin-monobody proteins in the nucleus. HeLa cells were incubated with AF-488 
labeled toxin-ML3-NLS or toxin-AS25-NLS or toxin-AS25 (without NLS) for 2.5h, 
washed and incubated in growth medium for the indicated total times. The fluorescence 
intensity of the 488 nm signal in the nucleus stained with Hoechst was quantified from 
confocal microscopy images of live cells. Each dot represents the mean 488 nm 
fluorescence in the nucleus of a single cell, normalized to the mean of the control cells 
incubated with unlabeled toxin-AS25-NLS. P-values were calculated using a Welch two-
sample t-test. Boxplots represent the median value, the first and third quartiles (lower and 
upper hinges) and the smallest and largest value within 1.5 times the interquartile range 
(lower and upper whiskers). An independent repeat of the experiment with additional 
timepoints is shown in Supplementary Fig. 5D.
Figure 5. Delivery of toxin-VHL-ML3 in Jurkat cells. (a) A4GALT-transduced Jurkat 
cells were treated with doxycycline for 24h to induce Gb3 expression (blue, orange and 
purple lines) or left untreated (red and green lines). Uninduced cells were incubated with 
BG-647 labeled toxin-SNAP-ML3 for 30 minutes (green line); doxycycline-induced cells 
were incubated with unlabeled toxin-SNAP-ML3 for 30 minutes, washed and 
subsequently incubated with BG-647 (orange line); doxycycline-induced cells were 
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incubated with BG-647 labeled toxin-SNAP-ML3 for 30 minutes (purple line). All cells 
were washed and analyzed by flow cytometry. One representative plot is shown out of 2 
biological repeats. (b) Expression of Gb3 was induced by addition of doxycycline in 
Jurkat cells as indicated and cells were incubated for 48 hours with the indicated proteins, 
washed and lysed. The cell lysate was immunoblotted with antibodies against Lck, Actin 
and penta-His. (c) Quantification of the Lck immunoblot normalized to Actin and to the 
control where no protein was added. Each dot represents a biological repeat of the 
experiment. Toxin-VHL-MbCtrl means that either toxin-VHL-HA4_YA or toxin-VHL-
AS25 was used as a control (2 repeats of each). P-values were calculated using a two-
tailed t-test. (*p<0.05, **p<0.005) Error bars indicate the SD of the repeats. (d) Jurkat 
cells expressing Gb3 (induced with doxycycline) were incubated for 48 hours with the 
indicated proteins. Cells were stimulated with an anti-TCR antibody for 5 minutes and 
lysed. Immunoblot analysis of the cell lysate with antibodies against Lck, Actin, 
phosphorylated Y319 residue of Zap70, total Zap70 and His-tagged proteins are shown 
from top to bottom. One representative blot is shown from 3 biological repeats. 
Quantification of the Lck immunoblot normalized to Actin is shown in Supplementary 
Fig. 7 (e) Quantification of the pY319 Zap70 immunoblot normalized to the loading 
control (Actin or total Zap70) and to the unstimulated cells incubated with toxin-VHL-
HA4_YA from 3 biological repeats. P-values were calculated using a ratio paired t-test. 
(*p<0.05) Error bars indicate the SD of the repeats.
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